Announcements Trials
Browse Landscape

Phase

Phase 3 11Phase 2 7Phase 2/3 3Phase 4 2Phase 1 2Phase NA 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Fatigue 2Neoplasms 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × OTHER × Methylphenidate × Clear all
NCT02361125 2022-01-04

Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue - PRN Methylphenidate

M.D. Anderson Cancer Center

Phase 1 Completed
31 enrolled

Fatigue

NCT01164956 2019-04-26

Methylphenidate for Cancer-Related Fatigue

Dana-Farber Cancer Institute

Phase 1 Terminated
3 enrolled 7 charts

Fatigue, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡